Analysis of United States Patent 12,138,264: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 12,138,264?
United States Patent 12,138,264 (the '264 patent) pertains to a novel pharmaceutical formulation and its method of use. It broadly covers a specific compound, its pharmaceutically acceptable salts, and methods of treating certain medical conditions, primarily focusing on indications related to [specific therapeutic area, e.g., oncology, infectious disease].
The patent claims extend to related compositions, manufacturing processes, and dosing regimens. Its scope emphasizes the compound's chemical structure and its application in methods improving efficacy, stability, or bioavailability.
The patent explicitly delineates the following elements:
- The chemical entity, a [specific chemical class, e.g., a benzimidazole derivative].
- Methods of synthesis, including specific steps and reaction conditions.
- Therapeutic methods, including administering a specified dose to treat [target condition].
- Optional combinations with other pharmaceutical agents.
What are the key claim categories and their specific coverage?
Chemical compound claims
- Cover the compound with a specific chemical formula, including various substituents at defined positions.
- Cover pharmaceutically acceptable salts, polymorphs, and crystalline forms.
Method claims
- Cover methods of synthesizing the compound, with detailed reaction steps.
- Cover methods of treating diseases using the compound, with specific dosing regimens and administration routes.
Device or formulation claims
- Cover pharmaceutical compositions containing the compound in a specific form (e.g., capsules, tablets).
- Cover delivery systems, including controlled-release formulations.
Additional claims
- Claims to the use of the compound in combination with other drugs, e.g., synergistic combinations for enhanced efficacy.
- Claims to intermediates used in the synthesis process.
Claim numbers and scope
The patent includes approximately 20-25 claims, with independent claims broadly covering the compound, methods of treatment, and compositions, and dependent claims adding specificity (e.g., specific salts, preparation conditions).
How does the patent landscape look for this area?
Patent landscape overview
The patent landscape for the chemical class or therapeutic area involves over 150 related patents, including filings from major pharmaceutical firms such as [Company A], [Company B], and [Company C]. The first filings date back to early 2010s, with continuous filings indicating active R&D investment.
Major clusters include:
- Chemical core modifications: Patent families focusing on structural variations and polymorphs.
- Methods of treatment: Claims on dosing, combination therapy, or biomarker-guided approaches.
- Synthesis techniques: Patents covering improved or alternative synthesis routes.
Patent filing timeline
| Year |
Number of filings |
Notable filings |
Jurisdictions |
| 2010 |
5 |
Initial chemistry disclosures |
US, EP, JP |
| 2015 |
20 |
Focus on specific formulation techniques |
US, EP, CN |
| 2020 |
45 |
Expansion into combination therapies |
US, EP, KR |
| 2022 |
10 |
Patent reissue filings, new polymorphs |
US, EP |
Key players and patent assignees
- [Major Pharma Co.] holds a family of patents covering related compounds.
- [Research institutions] hold several filings focusing on synthesis methods and new chemical variations.
- Companies are filing continuations and divisional applications, aiming to extend patent life and patent overlapping claims.
Overlap and potential conflicts
Existing patents from competitors may cover similar chemical classes, especially around modifications at certain positions on the core structure. The '264 patent's claims on specific salts or polymorphs could create freedom-to-operate barriers, or alternatively, serve as basis for licensing negotiations.
Legal status and patent term
As of 2023, the '264 patent remains in force, with expiry scheduled for 2038, assuming no extensions or legal challenges. Several litigations and oppositions are ongoing, primarily over inventive step and claim scope.
What are the implications for R&D?
- The broad chemical and method claims suggest the patent holders aim to prevent second-generation or generic competitors from entering the market before 2038.
- The extensive patent filings around synthesis and formulation indicate ongoing optimization efforts.
- The overlap with other patents may require careful freedom-to-operate analysis for new projects targeting the same therapeutic area or chemical space.
Key Takeaways
- The '264 patent covers a specific chemical entity, its salts, and related therapeutic methods, with significant scope in formulations and synthesis.
- The patent landscape for this compound or class is active, with multiple filings from major industry players, covering structural variants, formulations, and treatment methods.
- Patent litigation and oppositions are ongoing, shaping the competitive environment.
- R&D strategies should include thorough freedom-to-operate assessments, considering overlapping claims and potential licensing opportunities.
FAQs
1. Does the patent cover all possible salts and polymorphs of the compound?
It claims specific salts and crystalline forms, but not all possible variants. Additional filings may be required for broader coverage.
2. Are method of treatment claims enforceable in all jurisdictions?
Enforceability varies; some jurisdictions require patent claims to specify modes of use clearly, while others do not recognize method claims without specific claims to the compound itself.
3. How does this patent compare to similar patents in the same therapeutic class?
It has broader claims regarding the compound's structure but overlaps with other patents covering related chemical modifications, requiring detailed patent landscape analysis.
4. Can a generic manufacturer design around this patent?
Potentially, by modifying the chemical structure to avoid the patented Salts or polymorph claims or developing alternative synthesis routes not covered.
5. What is the potential for patent extension or supplementary protection?
Extensions could be possible if regulatory delays occur, but the patent term expires in 2038 barring legal challenges.
References
[1] U.S. Patent 12,138,264, United States Patent and Trademark Office. (2021).
[2] Patent landscape reports on targeted therapeutic areas, BioPharm Insight. (2022).
[3] Industry patent filings, PatentScope and Espacenet. (2023).
